Collectively, these findings demonstrate that 4-MD engages multiple, non-redundant cell death pathways through coordinated ROS-MAPK-AMPK/mTOR/ULK1 signaling, highlighting its potential to overcome therapeutic resistance in heterogeneous neuroblastoma cells. This evidence concerns the gene MTOR and neuroblastoma.